Getawa Solomon, Fentahun Abaynesh, Adane Tiruneh, Melku Mulugeta
Department of Hematology and Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
HIV AIDS (Auckl). 2021 Feb 25;13:229-237. doi: 10.2147/HIV.S294046. eCollection 2021.
HIV/AIDS-associated morbidity and mortality have reduced since the introduction of antiretroviral therapy (ART). Treatment failure is one of the causes of mortality, morbidity, and the development of drug-resistant viral strains. Therefore, this research aims to assess the prevalence and associated factors of treatment failure among children with HIV/AIDS on antiretroviral therapy attending the University of Gondar Specialized Referral Hospital, Northwest Ethiopia.
A retrospective study was conducted on 200 children registered for ART from 2005 to 2017. Data regarding patients' socio-demographic, baseline clinical characteristics, and treatment-related information were collected through a review of their medical records. Data were entered into Epi-info version 3.5.3 and analyzed using statistical package for social sciences (SPSS) version 21 software. To summarize characteristics of the study participant's descriptive statistics were done. Bivariable and multivariable binary logistic regression were fitted to identify factors associated with treatment failure. The odds ratio and 95% confidence interval (CI) were calculated to assess the strength of the association and P-value<0.05 in the multivariable regression was considered as statistically significant.
The prevalence of ART failure was 12.5% (95% CI: 7.88, 17.12), clinical failure was the most common followed by immunologic failure with only a small proportion having both clinical and immunologic failure. The mean time to develop treatment failure after initiation of the first-line regimen was 22.28 ± 24.00 months. Being male (AOR= 3.15; 95% CI: 1.18-8.39), co-infected with tuberculosis (TB) at baseline (AOR= 2.37; 95% CI: 1.23-8.84), being on ART for a long period (>36 months) (AOR= 1.01; 95% CI: 1.34-2.89), and regimen change (AOR=9.22; 95% CI: 3.36-25.03) were factors of ART failure.
In this study, there is significant treatment failure among HIV-infected children. Having co-infection, being on ART for a long period, regimen change, and being male were found to be independent factors of treatment failure in children. Therefore, timely identification and monitoring of ART failure should be necessary to enhance the benefit and to prevent further complications. Prophylaxis for opportunistic infections such as co-trimoxazole preventive therapy should continue to recover the immunological status of the child.
自引入抗逆转录病毒疗法(ART)以来,与艾滋病毒/艾滋病相关的发病率和死亡率有所降低。治疗失败是导致死亡、发病以及耐药病毒株产生的原因之一。因此,本研究旨在评估在埃塞俄比亚西北部贡德尔大学专科医院接受抗逆转录病毒治疗的艾滋病毒/艾滋病儿童中治疗失败的患病率及相关因素。
对2005年至2017年登记接受抗逆转录病毒治疗的200名儿童进行了一项回顾性研究。通过查阅他们的病历收集有关患者社会人口统计学、基线临床特征和治疗相关信息的数据。数据录入Epi-info 3.5.3版本,并使用社会科学统计软件包(SPSS)21版软件进行分析。为总结研究参与者的特征,进行了描述性统计。采用双变量和多变量二元逻辑回归来确定与治疗失败相关的因素。计算比值比和95%置信区间(CI)以评估关联强度,多变量回归中P值<0.05被认为具有统计学意义。
抗逆转录病毒治疗失败的患病率为12.5%(95%CI:7.88,17.12),临床失败最为常见,其次是免疫失败,只有一小部分同时存在临床和免疫失败。开始一线治疗方案后出现治疗失败的平均时间为22.28±24.00个月。男性(调整后比值比[AOR]=3.15;95%CI:1.18 - 8.39)、基线时合并感染结核病(TB)(AOR=2.37;95%CI:1.23 - 8.84)、接受抗逆转录病毒治疗时间较长(>36个月)(AOR=1.01;95%CI:1.34 - 2.89)以及治疗方案改变(AOR=9.22;95%CI:3.36 - 25.03)是抗逆转录病毒治疗失败的因素。
在本研究中,艾滋病毒感染儿童中存在显著的治疗失败情况。发现合并感染、接受抗逆转录病毒治疗时间长、治疗方案改变以及男性是儿童治疗失败的独立因素。因此,有必要及时识别和监测抗逆转录病毒治疗失败情况,以提高疗效并预防进一步并发症。应继续进行复方新诺明预防性治疗等机会性感染的预防,以恢复儿童的免疫状态。